Condition (MeSH)
Netherton Syndrome
ClinicalTrials.gov lists 22 trials for Netherton Syndrome or a narrower condition beneath it. Quoin Pharmaceuticals has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Netherton Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Netherton Syndrome trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2014 | 3 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Netherton Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 2 |
| Phase 2/3 | 6 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |
How many Netherton Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 9 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Netherton Syndrome trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Quoin Pharmaceuticals | 4 |
| Daiichi Sankyo | 3 |
| Boehringer Ingelheim | 2 |
| Azitra Inc. | 1 |
| BioCryst Pharmaceuticals | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Netherton Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DS-2325a | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Secukinmab | 2 |
| QRX003, 4% Lotion | 2 |
| QRX003 | 1 |
| BPR277 ointment | 1 |
| BLOOD SAMPLES | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Netherton Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization-GERD | 2 | 1 |
| Abortion spontaneous | 1 | 1 |
| Anaphylactic reaction | 1 | 1 |
| Basal cell carcinoma | 1 | 1 |
| Chronic sinusitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Netherton Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Unveiling serine protease activity profiles in Netherton syndrome skin across clinical subtypes by noninvasive analysis. | American journal of physiology. Cell physiology | 2025 | Yes |
| Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses. | The Journal of allergy and clinical immunology | 2022 | Yes |
| Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. | Human gene therapy. Clinical development | 2013 | Yes |
| The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. | Archives of dermatology | 2010 | Yes |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Netherton syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Netherton syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Netherton syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Netherton syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Netherton syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Netherton syndrome | 634 | Exact | Orphadata Science knowledge files, Product 1 |
| Netherton syndrome | 634 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.